ZANOVELLO, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.538
AS - Asia 3.152
EU - Europa 2.389
SA - Sud America 714
AF - Africa 627
OC - Oceania 59
Continente sconosciuto - Info sul continente non disponibili 30
Totale 19.509
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.211
SG - Singapore 939
CN - Cina 890
BR - Brasile 509
HK - Hong Kong 489
DE - Germania 390
IT - Italia 314
FI - Finlandia 267
SE - Svezia 195
UA - Ucraina 164
VN - Vietnam 152
GB - Regno Unito 138
RU - Federazione Russa 118
PL - Polonia 116
FR - Francia 115
KR - Corea 71
NL - Olanda 59
IN - India 53
AT - Austria 42
CI - Costa d'Avorio 39
CA - Canada 37
IE - Irlanda 35
ZA - Sudafrica 32
EC - Ecuador 31
JP - Giappone 31
AR - Argentina 30
CH - Svizzera 30
CO - Colombia 29
TR - Turchia 29
AZ - Azerbaigian 26
ES - Italia 26
IQ - Iraq 26
SI - Slovenia 26
AL - Albania 24
UZ - Uzbekistan 24
MA - Marocco 23
MX - Messico 23
PE - Perù 23
JO - Giordania 22
KG - Kirghizistan 22
RO - Romania 22
AO - Angola 21
GH - Ghana 21
MD - Moldavia 21
ME - Montenegro 21
SA - Arabia Saudita 21
CL - Cile 20
CW - ???statistics.table.value.countryCode.CW??? 20
DZ - Algeria 20
EE - Estonia 20
KH - Cambogia 20
ZM - Zambia 20
BE - Belgio 19
DK - Danimarca 19
LY - Libia 19
PY - Paraguay 19
TH - Thailandia 19
TN - Tunisia 19
AE - Emirati Arabi Uniti 18
BB - Barbados 18
BZ - Belize 18
GT - Guatemala 18
HN - Honduras 18
HR - Croazia 18
HU - Ungheria 18
JM - Giamaica 18
PK - Pakistan 18
YT - Mayotte 18
AU - Australia 17
GR - Grecia 17
IL - Israele 17
SO - Somalia 17
BF - Burkina Faso 16
CR - Costa Rica 16
CV - Capo Verde 16
ID - Indonesia 16
IR - Iran 16
IS - Islanda 16
LA - Repubblica Popolare Democratica del Laos 16
NP - Nepal 16
PA - Panama 16
PS - Palestinian Territory 16
TT - Trinidad e Tobago 16
UY - Uruguay 16
AM - Armenia 15
BG - Bulgaria 15
BJ - Benin 15
CG - Congo 15
CU - Cuba 15
GN - Guinea 15
GP - Guadalupe 15
MU - Mauritius 15
NA - Namibia 15
PR - Porto Rico 15
TJ - Tagikistan 15
BD - Bangladesh 14
BW - Botswana 14
CD - Congo 14
CZ - Repubblica Ceca 14
GE - Georgia 14
Totale 18.856
Salva come PNG Salva come JPEG
Città #
Fairfield 1.641
Woodbridge 1.403
Houston 1.107
Chandler 1.009
Ann Arbor 983
Ashburn 903
Jacksonville 640
Seattle 593
Wilmington 583
Cambridge 569
Singapore 534
Hong Kong 467
Princeton 275
Beijing 258
Boardman 245
San Diego 224
Padova 165
Santa Clara 160
Nanjing 117
Des Moines 112
Helsinki 104
Bytom 89
Dong Ket 81
Roxbury 78
Medford 76
Munich 64
Hefei 59
Los Angeles 56
Seoul 51
Guangzhou 43
Hebei 41
Abidjan 37
Nanchang 37
São Paulo 36
New York 34
London 30
Dublin 29
Ho Chi Minh City 29
Shenyang 27
Norwalk 26
Baku 24
Nuremberg 24
Vienna 23
Amman 22
Accra 21
Belo Horizonte 21
Changsha 21
Jiaxing 21
Tashkent 21
Tianjin 21
Bishkek 20
Phnom Penh 20
Kharkiv 19
Milan 19
Lusaka 18
Buffalo 17
Dallas 17
Ljubljana 17
Podgorica 17
Willemstad 17
Bridgetown 16
Luanda 16
Shanghai 16
Brooklyn 15
Chicago 15
Conakry 15
Jinan 15
Johannesburg 15
Kingston 15
Praia 15
Tokyo 15
Cotonou 14
Dili 14
Dushanbe 14
Guatemala City 14
Kinshasa 14
Montevideo 14
Ouagadougou 14
Reykjavik 14
Rio de Janeiro 14
Vientiane 14
Washington 14
Amsterdam 13
Falls Church 13
Havana 13
Kampala 13
Kigali 13
Lima 13
Mamoudzou 13
Nouakchott 13
Nürnberg 13
Ogden 13
Panama City 13
Quito 13
Borås 12
Chisinau 12
Council Bluffs 12
Dearborn 12
Detroit 12
Hanoi 12
Totale 13.965
Salva come PNG Salva come JPEG
Nome #
A circulating miRNA assay as a first-line test for prostate cancer screening 252
Cellular pharmacology of PNU-159682, a liver microsomal metabolite of methoxymorpholinyl doxorubicin (Nemorubicin; MMDX) 245
T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells 237
A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors 227
A coordinate deregulation of microRNAs expressed in mucosa adjacent to tumor predicts relapse after resection in localized colon cancer 227
Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. 223
Reverse immunoediting: When immunity is edited by antigen 209
A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. 208
WT1 loss attenuates the TP53-induced DNA damage response in T-cell acute lymphoblastic leukemia 207
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells 192
Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes 181
MiR-142-3p Prevents Macrophage Differentiation during Cancer-Induced Myelopoiesis 178
Immunogenetic aspects of erosive osteoarthritis of the hand in patients from northern Italy 176
Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells 174
Biodistribution imaging of a paclitaxel-hyaluronan bioconjugate 172
Anti-L-selectin monoclonal antibody treatment in mice enhances tumor growth by preventing CTL sensitization in peripheral lymph nodes draining the tumor area 170
Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer 170
Reconstruction of gene regulatory modules from RNA silencing of IFN-α modulators: Experimental set-up and inference method 168
A site-selective hyaluronan-interferonα2a conjugate for the treatment of ovarian cancer 168
Circulating miRNA-375 as a potential novel biomarker for active Kaposi’s sarcoma in AIDS Patients 167
Cancer rejection by the immune system: forcing the check-points of tumor immune escape. 164
MODULATION OF MICRORNA EXPRESSION IN HUMAN T CELL DEVELOPMENT: TARGETING OF NOTCH3 BY MIR-150 164
DNA immunization in mice against virus-induced tumor antigens. 162
Clonal heterogeneity of melanoma in a paradigmatic case study: future prospects for circulating melanoma cells 161
Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma 160
Small noncoding RNAs in cells transformed by human T-cell leukemia virus type 1: a role for a tRNA fragment as a primer for reverse transcriptase. 160
Interaction of lymphokine-activated killer cells with susceptible targets does not induce second messenger generation and cytolytic granule exocytosis 158
A paclitaxel-hyaluronan bioconjugate exerts a high in vivo therapeutic activity against ovarian cancer 155
Cross-talk between GLI transcription factors and FOXC1 promotes T-cell acute lymphoblastic leukemia dissemination 154
Silencing of miR-182 is associated with modulation of tumorigenesis through apoptosis induction in an experimental model of colorectal cancer 153
A gene expression signature associated with survival in metastatic melanoma 151
Human miRNome profiling in colorectal cancer and liver metastasis development 150
Glycolytic Phenotype and AMP Kinase Modify the Pathologic Response of Tumor Xenografts to VEGF Neutralization 148
Survivin expression and prognostic significance in pediatric malignant peripheral nerve sheath tumors (MPNST) 148
Myeloid-derived suppressor cell role in tumor-related inflammation 147
Characterization of Clinical and Molecular Features Related to the Downregulated Expression of μ-Protocadherin in Colorectal Cancer. 147
Role of microRNAs in HTLV-1 infection and transformation 145
Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1 145
Natural history of M-MSV tumors in mice carrying endogenized Moloney leukemia virus. 143
CTL response and protection against P815 tumor challenge in mice immunized with DNA expressing the tumor-specific antigen P815A. 143
DNA-based vaccination against tumors expressing the P1A antigen 143
Circulating miR-182 is a biomarker of colorectal adenocarcinoma progression 142
HYTAD1-p20: A new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer 140
CTL Analysis for Tumor Vaccines. 138
An integrative framework identifies alternative splicing events in colorectal cancer development. 138
Dissecting the molecular regulatory networks in human myeloid-derived suppressor cells 135
Reprogramming T Lymphocytes for Melanoma Adoptive Immunotherapy by T-Cell Receptor Gene Transfer with Lentiviral Vectors 134
Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies 134
Role of arginine metabolism in immunity and immunopathology. 134
Immune response to Moloney-murine leukemia virus-induced antigens in bone marrow 133
Role of infectious virus expression and immune response in retrovirus-induced oncogenesis. 132
Effective genetic vaccination with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase. 131
Calcium and Inositolphosphates In the Activation of T-cell-mediated Cytotoxicity 131
Regulation of immune responses by L- arginine metabolism 130
Lack of T-cell mediated cytotoxicity in M-MSV system depending on H-2 haplotypes. 130
Study of Some Early Immunological Parameters In Aging Humans 129
Derangement of immune responses by myeloid suppressor cells 128
Immunotherapy for EBV-associated malignancies 128
Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy 128
Melanoma-restricted genes 128
Virus-Specific Cytotoxic CD4+ T Cells for the Treatment of EBV-Related Tumors. 127
Adoptive cell therapy against EBV-related malignancies: a survey of clinical results 127
L-arginine metabolism in myeloid cells controls T-lymphocyte functions 127
Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination 126
Delivery of methoxymorpholinyl doxorubicin by interleukin 2-activated NK cells: effect in mice bearing hepatic metastases 126
ADOPTIVE TRANSFER OF LYMPHOKINE-ACTIVATED KILLER-CELLS LOADED WITH 4'-DEOXY-4'-IODODOXORUBICIN - THERAPEUTIC EFFECT IN MICE BEARING LUNG METASTASES 126
Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells 125
Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: A novel target for therapeutic intervention 124
Myeloid-derived suppressor cell heterogeneity and subset definition 124
Lack of M-MuSV tumour regression associated with T lymphocyte tolerance. 124
ANTITUMOR EFFICACY OF LYMPHOKINE-ACTIVATED KILLER-CELLS LOADED WITH RICIN AGAINST EXPERIMENTALLY INDUCED LUNG METASTASES 123
MAGE, BAGE and GAGE gene expression in human rhabdomyosarcomas 123
Protein tyrosine kinases and phosphatases control apoptosis induced by extracellular adenosine 5'-triphosphate. 123
Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells 122
Tolerance to viral antigens in Mov-13 mice carrying endogenized Moloney-murine leukemia virus. 122
Chemotactic Cues for NOTCH1-Dependent Leukemia 122
Common cancer biomarkers 121
CD45 regulates apoptosis induced by extracellular adenosine triphosphate and cytotoxic T lymphocytes 121
Tumor-Induced Tolerance and Immune Suppression Depend on the C/EBPbeta Transcription Factor. 121
GM-CSF and IL-6 induce tolerogenic myeloid-derived suppressor cells through C/EBP beta and allow long term islet allograft survival 121
Extracellular ATP as a possible mediator of cell-mediated cytotoxicity 119
Tumor-induced immune dysfunctions caused by myeloid suppressor cells 119
INHIBITION OF PROTEIN-TYROSINE PHOSPHORYLATION PREVENTS T-CELL-MEDIATED CYTOTOXICITY 119
In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer 117
Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150 117
miR-22-3p Negatively Affects Tumor Progression in T-Cell Acute Lymphoblastic Leukemia 117
PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models. 115
Impact of gamma-chain cytokines on EBV-specific T cell cultures 114
IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice 114
Extracellular ATP causes lysis of mouse thymocytes and activates a plasma membrane ion channel 113
Optimization of a DNA vaccination protocol for CTL induction against tumors expressing the weakly immunogenic P1A antigen 111
Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma 111
Functional activityin vivo of effector T cell populations III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clone 111
Peritoneal tumor carcinomatosis: pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs. 110
Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes 109
Therapeutic effect of interleukin 12 on mouse haemangiosarcomas is not associated with an increased anti-tumour cytotoxic T-lymphocyte activity 107
Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient 107
Crosstalk between Hedgehog pathway and the glucocorticoid receptor pathway as a basis for combination therapy in T-cell acute lymphoblastic leukemia 107
Therapeutical effect of 4′-deoxy-4′-iododoxorubicin-loaded LAK cells in mice bearing lung metastases 106
Predicting tumor outcome following cancer vaccination by monitoring quantitative and qualitative CD8(+) T cell parameters 106
Totale 14.399
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.995
article - articoli 65.139
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 739
Totale 132.873
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.481 0 0 83 133 79 123 59 198 244 184 201 177
2021/20222.385 68 302 350 146 80 164 201 214 87 47 290 436
2022/20231.901 403 234 56 232 290 259 10 116 187 15 68 31
2023/2024855 48 107 91 55 84 100 73 62 31 27 80 97
2024/20253.163 24 166 140 119 463 143 124 294 298 132 498 762
2025/20263.052 461 1.184 1.407 0 0 0 0 0 0 0 0 0
Totale 19.581